ArticleFrontiers in pharmacology2021
Ginsenosides Improve Nonalcoholic Fatty Liver Disease
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Ginseng Bioactive Components as Gut-Brain Axis-Targeted Modulators: Therapeutic Potential and Mechanisms in Multifactorial Diseases.Nutrients · 2026Pooled it
- The Green Path to Liver Health: Herbal Solutions for Non-alcoholic Steatohepatitis.Cardiovascular & hematological disorders drug targets · 2025Pooled it
- Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease.Frontiers in pharmacology · 2025Pooled it
- The Efficacy ofNutrients · 2023Pooled it
- Review
- Ginsenosides for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease: A Research Update.Nutrients · 2026Review
- Gut microbiota-mediated regulation of lipid metabolism by single herbal medicines: a review focused on cold/hot properties.Chinese medicine · 2026Review
- Crosstalk along the gut-liver axis modulates glutathione and cadmium-induced hepatotoxicity.Frontiers in immunology · 2026Review
- Therapeutic effect of ginseng: a non-antibiotic approach to preventing pathogenic bacterial infections and restoring gut microbiota composition.Frontiers in pharmacology · 2026Review
- Potential mechanisms of natural metabolites and botanical drugs foumulae for the treatment of non-alcoholic fatty liver disease: targeting the gut microbiota to modulate the immune system.Frontiers in pharmacology · 2025Review
- The Hepatoprotective Effects of Ginsenoside from Ginseng: A Review of Molecular Mechanisms and Therapeutic Potentials.Current pharmaceutical biotechnology · 2025Review
- A Review of the Therapeutic Potential of Ginseng and Its Bioactive Components in Nonalcoholic Fatty Liver Disease.Drug design, development and therapy · 2025Review
- Ginseng and its functional components in non-alcoholic fatty liver disease: therapeutic effects and multi-target pharmacological mechanisms.Frontiers in pharmacology · 2025Review
- Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease.Frontiers in pharmacology · 2025Review
- Korean Red Ginseng alleviates dextran sodium sulfate-induced colitis through gut microbiota modulation in mice.Journal of ginseng research · 2024Article
- A Scoping Review on Hepatoprotective Mechanism of Herbal Preparations through Gut Microbiota Modulation.Current issues in molecular biology · 2024Article
- Ginsenoside RgNutrients · 2024Article
- Herbal medicine and gut microbiota: exploring untapped therapeutic potential in neurodegenerative disease management.Archives of pharmacal research · 2024Review
- Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota.Frontiers in cellular and infection microbiology · 2024Review
- Current View on How Human Gut Microbiota Mediate Metabolic and Pharmacological Activity ofEndocrine, metabolic & immune disorders drug targets · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginseng, the root and rhizome of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.